Zhengye Biotechnology Holding Limited (ZYBT)
NASDAQ: ZYBT · Real-Time Price · USD
8.40
+0.84 (11.11%)
At close: Aug 13, 2025, 4:00 PM
8.24
-0.16 (-1.90%)
After-hours: Aug 13, 2025, 5:34 PM EDT
ZYBT Revenue
In the year 2024, Zhengye Biotechnology Holding had annual revenue of 186.36M CNY, down -11.95%. Zhengye Biotechnology Holding had revenue of 91.41M in the half year ending December 31, 2024, a decrease of -33.24%.
Revenue (ttm)
186.36M CNY
Revenue Growth
-11.95%
P/S Ratio
15.02
Revenue / Employee
672,765 CNY
Employees
277
Market Cap
398.09M USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 186.36M | -25.30M | -11.95% |
Dec 31, 2023 | 211.65M | -48.62M | -18.68% |
Dec 31, 2022 | 260.27M | 46.20M | 21.58% |
Dec 31, 2021 | 214.07M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionZYBT News
- 5 weeks ago - Zhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial Results - PRNewsWire
- 2 months ago - Zhengye Biotechnology Holding Limited Receives NASDAQ Notice Related to Late Filing of Form 20-F - GlobeNewsWire
- 7 months ago - Zhengye Biotechnology Holding Limited Announces Full Exercise of Underwriters' Over-Allotment Option - GlobeNewsWire
- 7 months ago - U.S. IPO Weekly Recap: Flowco Launches First Major IPO Of 2025 As Smithfield, Others Join The Pipeline - Seeking Alpha
- 7 months ago - Zhengye Biotechnology Holding Limited Announces Closing of Initial Public Offering - GlobeNewsWire
- 7 months ago - Zhengye Biotechnology Holding Limited Announces Pricing of Initial Public Offering - GlobeNewsWire
- 1 year ago - Zhengye Biotechnology's Growth Slows As It Seeks U.S. IPO - Seeking Alpha
- 1 year ago - Chinese animal health company Zhengye Biotechnology Holding files for a $20 million US IPO - Renaissance Capital